Legacy Clinical Solutions: Tandem Clinical Research, LLC - Clinedge - PPDS
Welcome,         Profile    Billing    Logout  
 0 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fatakia, Adil
ACHIEVE-2, NCT06192108: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin

Recruiting
3
888
Europe, US, RoW
Orforglipron, LY3502970, Dapagliflozin
Eli Lilly and Company
Type 2 Diabetes
10/25
10/25
NCT05758415: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Active, not recruiting
3
61
Europe, US, RoW
Secukinumab, AIN457, Placebo
Novartis Pharmaceuticals
Rotator Cuff Tendinopathy
10/24
12/24
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
REPOSA, NCT06146101: RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA

Recruiting
2/3
560
US
IHL-42X Low Dose, Phase 2 Investigational Product - IHL-42X Low dose, IHL-42X High Dose, Phase 2 Investigational Product - IHL-42X High dose, Placebo, Phase 2 Placebo, IHL-42X (Optimal Dose), Phase 3 Investigational Product - IHL-42X, Dronabinol, Phase 3 Comparator - Reference Listed Drug/Dronabinol, Acetazolamide, Phase 3 Comparator - Reference Listed Drug/Acetazolamide, Phase 3 Placebo
Incannex Healthcare Ltd
Obstructive Sleep Apnea
12/26
12/26
NCT04809376: Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

Active, not recruiting
2/3
602
US, RoW
Pentosan Polysulfate Sodium twice weekly, PPS twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Placebo, Pentosan Polysulfate Sodium Fixed Dose, Fixed Dose, Pentosan Polysulfate Sodium once weekly, PPS once weekly
Paradigm Biopharmaceuticals USA (INC)
Osteoarthritis, Knee
10/24
01/25
NCT06373146: A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

Recruiting
2
360
US, RoW
Tirzepatide, LY3298176, Mibavademab, REGN4461, Tirzepatide-Placebo, Mibavademab-Placebo
Eli Lilly and Company, Regeneron Pharmaceuticals
Obesity
12/25
04/26
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

Completed
2
797
NA
ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline
AEON Biopharma, Inc., PPD
Migraine
06/24
08/24
NCT06019000: Study of CYR-064 Versus Placebo in Patients.

Recruiting
2
150
US
CYR-064
Cyrano Therapeutics, Inc.
Hyposmia
09/24
01/25
HORIZON, NCT05583344: Phase 2b Study of GSK4532990 in Adults With NASH

Recruiting
2
246
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline
Nonalcoholic Fatty Liver Disease
09/25
12/25
CYPRESS, NCT05895552: A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain

Recruiting
2
384
US
RTA 901, BIIB143, Cemdomespib, RTA 901-Matching Placebo
Reata, a wholly owned subsidiary of Biogen
Diabetic Peripheral Neuropathic Pain
08/26
08/26
NCT03584737 / 2017-001604-30: Point-of-Care Immunoassay for Detection of Bacterial Sinusitis

Terminated
N/A
800
US
rapid in vitro diagnostic test, Sinu-Test®, bacterial culture, PCR assay
ENTvantage Dx, Beaufort
Sinusitis Bacterial
04/23
04/23
NCT06163404: Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant

Recruiting
N/A
50
US
Implantation of Spirair Nasal Device using the Spirair delivery system., SeptAlign
Spirair, Inc
Nasal Septal Deviation, Nasal Airway Obstruction
12/24
07/25
NCT05591989: Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects With Chronic Rhinitis (PARAGON)

Active, not recruiting
N/A
80
US
NEUROMARK System
Neurent Medical
Chronic Rhinitis
06/25
06/25
Odom, Jessie
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

Completed
2
797
NA
ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline
AEON Biopharma, Inc., PPD
Migraine
06/24
08/24

Download Options